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Localizing chronic Q fever: a challenging query
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Abstract
Background: Chronic Q fever usually presents as endocarditis or endovascular infection. We investigated whether
18F-FDG PET/CT and echocardiography were able to detect the localization of infection. Also, the utility of the
modified Duke criteria was assessed.
Methods: Fifty-two patients, who had an IgG titre of ≥ 1024 against C. burnetii phase I ≥ 3 months after primary
infection or a positive PCR ≥ 1 month after primary infection, were retrospectively included. Data on serology, the
results of all imaging studies, possible risk factors for developing proven chronic Q fever and clinical outcome were
recorded.
Results: According to the Dutch consensus on Q fever diagnostics, 18 patients had proven chronic Q fever, 14
probable chronic Q fever, and 20 possible chronic Q fever. Of the patients with proven chronic Q fever, 22% were
diagnosed with endocarditis, 17% with an infected vascular prosthesis, and 39% with a mycotic aneurysm. 56% of
patients with proven chronic Q fever did not recall an episode of acute Q fever. Ten out of 13 18F-FDG PET/CT-
scans in patients with proven chronic Q fever localized the infection. TTE and TEE were helpful in only 6% and 50%
of patients, respectively.
Conclusions: If chronic Q fever is diagnosed, 18F-FDG PET/CT is a helpful imaging technique for localization of
vascular infections due to chronic Q fever. Patients with proven chronic Q fever were diagnosed significantly more
often with mycotic aneurysms than in previous case series. Definite endocarditis due to chronic Q fever was less
frequently diagnosed in the current study. Chronic Q fever often occurs in patients without a known episode of
acute Q fever, so clinical suspicion should remain high, especially in endemic regions.
Keywords: Chronic Q fever, Coxiella burnetii, 18F-fluorodeoxyglucose positron emission tomography,
Echocardiography, Modified Duke criteria, Endocarditis
Background
Q fever is a zoonosis caused by Coxiella burnetii [1,2].
The acute form of Q fever is asymptomatic in 60% of pa-
tients. Patients with symptomatic disease usually present
with mild flu-like symptoms, pneumonia or hepatitis
[1,3]. Following primary infection, 1-5% of patients develop
chronic Q fever [1,4-6]. In the literature, the most described
localization of chronic Q fever is endocarditis, accounting
for 60-80% of cases [1,2,7,8]. Less frequently reported
manifestations of chronic Q fever include infections of
aneurysms or vascular prostheses (9% of cases), chronic
infections during pregnancy (5%) and other persistent in-
fections (8%), such as osteomyelitis and chronic hepatitis
[8,9]. However, following the recent Q fever epidemic in
the Netherlands [10-12], substantially more patients have
been diagnosed with an infected aneurysm or vascular
prosthesis [4,13].
The diagnosis of chronic Q fever is challenging. Per-
sistent infection usually develops insidiously and most
patients present with non-specific symptoms such as low-
grade fever, night sweats, weight loss, hepatosplenomegaly,
and a persistently raised erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) [1,3,8,14,15]. Both
serology and PCR aid the laboratory diagnosis of
chronic Q fever [16,17]. High levels of antibodies to
phase I more than 3 months after primary infection are
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found in chronic Q fever, whereas antibodies to phase II
predominate after convalescence from acute Q fever with-
out signs of chronic infection [5,16,18]. Localization of
infectious foci is important, because, in addition to
prolonged antimicrobial therapy, adjuvant therapeutic
measures such as surgical drainage or graft replacement
are often necessary [9,19]. This demonstrates the need
for reliable imaging methods. Infected aneurysms or
vascular prostheses can be identified by using computed
tomography (CT) or 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET/CT) [20-23]. In case
of Q fever endocarditis, however, the diagnosis is usu-
ally more complex and vegetations are rarely seen by
echocardiography [18,24,25]. This commonly delays the
diagnosis with several months [26].
From 2007 until 2010, the southern part of the
Netherlands faced the largest outbreak of Q fever ever
reported [4,10]. Physicians were confronted with an
increasing number of patients with suspected chronic
infection. The Dutch Q fever consensus group provided
a new guideline on the diagnosis of chronic Q fever
discriminating 3 categories: possible, probable and proven
chronic Q fever [15]. We investigated whether FDG-PET/
CT and echocardiography were able to detect the
localization of infection in all patients with chronic Q
fever treated at 2 hospitals specialized in Q fever in the
Netherlands. In addition, the utility of the modified Duke
criteria was assessed.
Methods
Study design and patients
All patients referred to Radboud University Nijmegen
Medical Centre and Canisius Wilhelmina Hospital in
Nijmegen, the Netherlands between August 2008 and
March 2011 were retrospectively included if they fulfilled
the following criteria: detection of C. burnetii DNA in
serum or tissue by PCR ≥ 1 month after primary infection
or an anti-phase 1 IgG titre of ≥ 1024 against C. burnetii
phase I ≥ 3 months following acute Q fever. Patients
without symptomatic acute infection were included if
anti-phase I IgG remained > 1024 over the course of > 3
months, or if there was positive serum PCR over the
course of > 1 month. The exclusion criterion was age < 18
years. For each patient a standardized case report form
was completed. According to the Dutch law, this study
was exempt from approval by an ethics committee, be-
cause of the retrospective character of this study and the
anonymous storage of data.
Diagnostic work-up
Serology and molecular detection
In 1994, the French National Centre for Rickettsial
Diseases proposed a cut-off value for anti-phase I IgG
of 1:800 for the diagnosis of chronic Q fever, using an
in-house immunofluorescence assay (IFA) [16]. This
cut-off value was adopted by the modified Duke criteria
[27] and is considered as diagnostic for chronic Q fever in
most literature. However, it is recently recognized that the
results of Q fever IFA vary according to the centre in
which they are carried out and the methods used (com-
mercially available immunofluorescence kits) [28,29]. This
also applies to the Dutch situation, where much higher
anti-phase I IgG titres were measured, especially during
the first months after acute infection [4]. The Dutch Q
fever consensus group proposed a cut-off value for anti-
phase I IgG of 1:1024 (immunofluorescence assay; Focus
Diagnostics, Inc., Cypress, CA, USA), measured at least
3 months after acute infection, for the diagnosis of
chronic Q fever in the Netherlands. In our study, sera
were also tested for C. burnetii antibodies using a com-
plement fixation test (CFT) (Institute Virion/Serion,
GmbH, Würzburg, Germany), testing only anti-phase II
antibodies.
Dutch consensus on chronic Q fever
The guideline on the classification of chronic Q fever [15],
that has been developed by the Dutch Q fever consensus
group, was used for diagnosis and classification of chronic
Q fever in this study. This guideline uses a combined ap-
proach based on risk factors, symptoms, microbiological
findings and imaging studies to discriminate 3 groups of
chronic Q fever:
Proven chronic Q fever Chronic Q fever is considered
proven in case of (1) a positive C. burnetii PCR on blood
or tissue without evidence for acute Q fever OR (2) IFA
anti-phase I IgG ≥ 1024 is present > 3 months after acute
infection AND definite endocarditis according to the
modified Duke criteria OR (3) IFA ≥ 1024 for anti-phase
I IgG AND proven vascular infection by abdominal
ultrasound (AUS), CT, or FDG-PET/CT.
Probable chronic Q fever Chronic Q fever is classified
as probable when IFA anti-phase I IgG ≥ 1024 is
present > 3 months after acute infection in combin-
ation with (1) valvular defects not meeting the modified
Duke criteria OR (2) a known aneurysm and/or vascu-
lar or cardiac valve prosthesis without signs of infection
by means of echocardiography, FDG-PET/CT, CT or
AUS OR (3) suspected osteomyelitis or hepatitis as
manifestation of chronic Q fever OR (4) pregnancy OR
(5) symptoms of chronic infection OR (6) granulomatous
tissue inflammation, histologically proven OR (7) being
immunocompromised.
Possible chronic Q fever Possible chronic Q fever is di-
agnosed when IFA anti-phase I IgG ≥ 1024 is present > 3
months after acute infection without manifestations
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meeting the criteria for proven or probable chronic Q
fever.
Modified Duke criteria
The modified Duke criteria for infective endocarditis
(IE) [27] were applied to all patients who underwent
echocardiography. As a result, patients were stratified
into 3 different groups: definite, possible and rejected IE.
Besides the well-adopted modified Duke criteria by Li
and colleagues [27], we also assessed 2 adjusted versions
of these criteria that have been used previously in stud-
ies on Q fever endocarditis. In the first adjustment, the
molecular (serum PCR) diagnosis of C. burnetii was con-
sidered as an additional major criterion [17,30]. In the
second adjustment, the echocardiographic minor criteria
that were eliminated by the modified Duke criteria in
2000 were reintroduced [27,31]. Echocardiographic minor
criteria include nodular valvular thickening, nonoscillating
targets, and new valvular fenestrations [31].
Imaging studies
Data on the following imaging studies were recorded:
AUS, CT, FDG-PET/CT, transthoracic echocardiography
(TTE) and transesophageal echocardiography (TEE).
FDG-PET/CT scans were performed according to inter-
national guidelines [32], using integrated PET/CT scan-
ners (Biograph™; Siemens, Knoxville, TN, USA or
Gemini™, Philips, Eindhoven, the Netherlands). All FDG-
PET/CT scans were performed in regular patient care and
therefore reviewed by specialized nuclear radiologists from
the department of Nuclear Medicine, Radboud University
Nijmegen Medical Centre, Nijmegen, the Netherlands, as
well as the department of Nuclear Medicine, Canisius
Wilhelmina Hospital, Nijmegen, the Netherlands. Higher
metabolic activity than physiological uptake in surround-
ing tissue in tissues with normally low physiological up-
take was considered to be indicative of infection. In
addition, irregular/localized FDG-uptake in tissues with
normally homogenous uptake was considered indicative
of infection. Each original report was used to score for
relevant abnormal findings. If these findings enabled
localization of infection, they were considered helpful.
Abnormal results that gave rise to further analysis, i.e.
suspected malignancy, but were not caused by chronic
Q fever, were labelled as unexpected findings.
Clinical data and outcome
Acute Q fever infection was regarded symptomatic if
patients were diagnosed with Q fever pneumonia or if
they could recall an episode of fever and pneumonia
and/or headache, that was not caused by other known
pathogens and that preceded the first positive Q fever
serology or positive serum PCR. Patients were regarded
to have pre-existing valvular disease if they were
previously known with a valvulopathy ≥ grade II (stenosis
or insufficiency, including congenital heart disease), or if
they had a medical history of valve replacement. Valvular
dysfunction was defined as the aggravation of pre-
existing valvulopathies to ≥ grade 2, the occurrence of
new valvulopathies of ≥ grade 2 or signs of artificial valve
dysfunction, or evidence of increasing heart failure or
the need for acute cardiac valve replacement. Data on
other possible risk factors for chronic Q fever were col-
lected (age, smoking, known aneurysm, presence of a
vascular prosthesis, immunosuppression or –deficiency,
other co-morbidity, and symptomatic acute Q fever).
The diagnostic workup was considered complete if both
echocardiography and screening for abdominal infection
were completed. Patients were considered to be cured if
their anti-phase I IgG antibody titre at least showed a
fourfold decrease or had declined to < 1024 during sub-
sequent serological testing, serum PCR had become
and/or remained negative, and diagnostic imaging dur-
ing follow-up showed no signs of active infection.
Statistical methods
All data were analyzed using SPSS (version 16.0, SPSS,
Inc.). Two-tailed Pearson’s chi-square tests or Fischer’s
exact tests were used to compare qualitative data,
whereas mean values were analyzed by Student’s t-tests.
Differences were considered to be statistically significant
at a p-value less than 0.05.
Results
All 52 patients fulfilling the inclusion criteria were
included in the study (Tables 1, 2, 3).
Proven chronic Q fever
Proven chronic Q fever was diagnosed in 18 patients
(Table 1). One patient developed systemic sclerosis during
treatment. Only 8 patients (44%) recalled an episode of
acute Q fever. Fourteen patients (78%) had symptomatic
chronic infection: fever (9/14), abdominal pain (4/14),
fatigue (3/14), weight loss (3/14), valvular dysfunction
(3/14), night sweats (2/14) or lumbar pain (2/14). In
two out of five patients with a pre-existing valvulopathy,
valvular dysfunction occurred (left ventricular function
deterioration due to Q fever endocarditis, and a new
dysfunction of an artificial cardiac valve, as a consequence
of Q fever endocarditis). One patient with valvular dys-
function was not familiar with a previous valvulopathy.
The mean interval between symptomatic acute Q fever
and the diagnosis of chronic Q fever was 12 ± 9 months
(range: 1-27). Definite endocarditis was diagnosed in 4 pa-
tients (22%), an infected vascular prosthesis in 3 patients
(17%), and an infected aneurysm in 7 patients (39%). One
of these patient had both a definite endocarditis and an
infected vascular prosthesis. In 5 patients (28%), no
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definite focus was identified. According to the modified
Duke criteria, 4 of these patients had possible endocarditis
and the fifth patient declined further diagnostic tests due
to his age and underlying medical condition.
The median anti-phase I IgG titre at diagnosis was 4096
(range: 256-65536), and the median height of CFT was
1280 (range: 0-20480) (Figures 1 and 2). One patient had
an anti-phase I IgG titre of only 256 and a negative CFT at
diagnosis, but was considered to have proven chronic Q
fever because serum PCR tested positive > 1 month follow-
ing primary infection. In 4 patients, the anti-phase I IgG
titre decreased to < 1024 after a mean duration of treat-
ment of 23.3 ± 7.9 months. By PCR, C. burnetii DNA was
successfully isolated from tissue samples (cardiac valve,
vascular prosthesis) in 5 out of 6 patients who underwent
surgery (1 patient underwent surgery twice). There was
1 positive PCR on fluid spontaneously draining from a
fistula between an abscess around a vascular prosthesis
and the skin. Four out of the 6 patients with positive
fluid/tissue PCR were analyzed by FDG-PET/CT, all of
which showed FDG-positive lesions. The other 2 were
already found to have definite IE according to the modi-
fied Duke criteria and no FDG-PET/CT was performed.
In these 2 patients, PCR was positive on infected cardiac
valves that were replaced by surgery. In 7 of 12 patients
with a positive serum PCR, PCR became negative after
an average of 3.6 ± 3.0 months. Two patients died when
PCR had not become negative yet, 1 patient was lost to
follow-up, and 2 patients still had a positive serum PCR
after 4 and 6 weeks of treatment, respectively.
A complete diagnostic work-up for chronic Q fever was
performed in 16 patients (89%) (Table 3). In 2 patients,
this work-up was incomplete: 1 patient refused further
analysis, and in 1 patient only echocardiography was done.
In 13 patients (72%), FDG-PET/CT was performed, which
was helpful in identifying the site of infection in 10 of
13 investigations (77%). All 7 patients with an aneurysm
as identified site of Q fever infection showed focal FDG-
uptake of the aneurysm. Furthermore, all 3 patients
with a vascular prosthesis as identified site of Q fever
infection showed focal uptake around the vascular pros-
thesis (Figure 3). In 4 out of the 13 above mentioned
FDG-PET/CT scans, FDG-positive lesions were con-
firmed by positive C. burnetii PCR on tissue. In all of
these 4 patients, FDG-PET/CT was conducted prior to
PCR. In the remaining patients, surgery was not indi-
cated and the lesions were very difficult to reach so tis-
sue PCR could not be performed. Unexpected findings
were observed in 4 patients (31%). As a result, 2 patients
required a biopsy because of focal FDG-uptake in the
lungs, leading to the diagnosis of lung carcinoma in 1
patient and fibrosis in the other. In 1 patient, massive
mediastinal lymphadenopathy was seen, eventually leading
to the diagnosis of systemic sclerosis. CT was performed
Table 1 Population characteristics of 52 patients with possible, probable and proven chronic Q fever*
Proven chronic Q fever: Probable chronic Q fever: Possible chronic Q fever:
Number of patients Number of patients Number of patients
(% or range) (% or range) (% or range)
General
Number of patients 18 14 20
Male sex 17 (94%) 8 (57%) 11 (55%)
Age at diagnosis 61 ± 16 yrs (26-88) 63 ± 12 yrs (43-84) 54 ± 15 yrs (26 – 81)
Mean BMI 25 ± 3 kg/m2 (18-30) 25 ± 4 kg/m2 (18-30) 25 ± 7 kg/m2 (19-41)
History of smoking 14 (78%) 9 (64%) 10 (50%)
Symptomatic acute infection 8 (44%) 12 (86%) 13 (65%)
Symptomatic chronic infection 14 (78%) 2 (14%) 0
Mean interval acute Q fever to analysis 12 ± 9 months (1-27) 16 ± 11 months (1-41) 7 ± 5 months (1-15)
Antibiotic therapy for chronic Q fever 18 (100%) 7 (50%) 3 (15%)
Localization of infection 13 (72%) 2 (14%) 0
Definite endocarditis 4 (22%)†‡ 2 (14%)§ 0
Vascular prosthesis 3 (17%)‡ 0 0
Mycotic aneurysm 7 (39%) 0 0
Focus unknown 5 (28%) 12 (86%) 20 (100%)
*Adapted from Wegdam-Blans et al. [15].
†Definite endocarditis according to the modified Duke criteria.
‡One patient had a definite endocarditis according to the modified Duke criteria and an infected vascular prosthesis.
§Possible endocarditis according to the modified Duke criteria.
Bold texts summarize components of the table.
Abbreviation: BMI body mass index.
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in 5 patients. Two of these investigations were done
initially (‘screening abdominal CT’), and the remaining 3
were conducted on account of a preceding abnormal
FDG-PET/CT-scan (one chest CT and two CT scans of
both chest and abdomen). Both screening CT-scans en-
abled localization of infection and were considered helpful.
The 3 CT-scans that were performed on the basis of
pathology on FDG-PET/CT all confirmed the abnormal
FDG-PET/CT findings. TTE was performed in 16
patients (89%); none of these examinations showed a
major criterion, whereas echocardiographic minor criteria
were seen in 12 patients (75%). Nevertheless, TTE was
regarded helpful in 1 patient where nodular valvular
thickening of an aortic bioprosthesis was seen. TEE was
performed in 6 patients (33%), 4 following a prior TTE. In
2 patients, an echocardiographic major criterion was
Table 2 Risk factors for developing chronic Q fever in 52 patients with possible, probable and proven chronic Q fever*
Proven chronic Q fever: Probable chronic Q fever: Possible chronic Q fever:
Number of patients Number of patients Number of patients
(% or range) (% or range) (% or range)
Number of patients 18 14 20
Pre-existing valvular disease†‡ 5 (28%) 4 (29%) 0
Mitral regurgitation 0 2 (14%) 0
Tricuspid regurgitation 0 1 (7%) 0
Bicuspid aortic valve 0 1 (7%) 0
Congenital (not bicuspid aortic valve) 1 (6%) 1 (7%) 0
Rheumatic fever 1 (6%) 0 0
Cardiac valve prosthesis† 4 (22%) 0 0
Biological aortic prosthesis 3 (17%) 0 0
Biological mitral prosthesis 1 (6%) 0 0
Mechanical aortic prosthesis 1 (6%) 0 0
Known aneurysm 8 (44%) 1 (7%) 0
Abdominal aortic aneurysm 7 (39%) 0 0
Dilated aortic root 1 (6%) 0 0
Cerebral aneurysm 0 1 (7%) 0
Vascular prosthesis 11 (61%) 4 (29%) 0
Abdominal aortic graft 7 (39%) 1 (7%) 0
Thoracic aortic graft 2 (11%) 0 0
PTA, iliacal or renal arteries 1 (6%) 2 (14%) 0
Goretex vascular shunt 1 (6%) 0 0
Coiling of cerebral aneurysm 0 1 (7%) 0
Immunocompromised 1 (6%) 6 (43%) 0
Immunosuppressive therapy 1 (6%) 4 (29%) 0
Myelodysplastic syndrome 0 2 (14%) 0
Co-morbidity† 18 (100%) 14 (100%) 8 (40%)
Chronic renal insufficiency 6 (33%) 4 (29%) 1 (5%)
Diabetes 3 (17%) 2 (14%) 4 (20%)
Active malignancy 1 (6%) 4 (29%) 1 (5%)
Systemic sclerosis 1 (6%) 2 (14%) 0
COPD 2 (11%) 3 (21%) 5 (25%)
Other§ 5 (28%) 3 (21%) 3 (15%)
*Adapted from Wegdam-Blans et al. [15].
†Multiple predisposing conditions are possible for a patient.
‡Including cardiac valve prosthesis; valvulopathies were considered clinically significant if ≥ grade II.
§Including severe peripheral arterial disease, coronary artery bypass graft, congestive heart failure and liver cirrhosis.
Bold texts summarize components of the table.
Abbreviations: PTA Percutaneous transluminal angioplasty, COPD Chronic obstructive pulmonary disease.
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Table 3 Diagnostics, treatment and outcomes in 52 patients with possible, probable and proven chronic Q fever*
Proven chronic Q fever: Probable chronic Q fever: Possible chronic Q fever:
Number of patients Number of patients Number of patients
(% or range) (% or range) (% or range)
Number of patients 18 14 20
Serum PCR 12 (67%) 0 0
Tissue PCR 6 (33%) 0 0
Anti-phase I IgG at diagnosis 4096 (256-65536) 2048 (1024-32768) 2048 (1024-16384)
CFT at diagnosis 1280 (0-20480) 320 (80-5120) 320 (40-2560)
Time to anti-phase I IgG <1024 (months) 23.3 ± 7.9 [n = 4] 12.6 ± 3.9 [n = 5] 7.5 ± 5.1 [n = 8]
Time to negative serum PCR 3.6 ± 3.0 [n = 7] NA NA
Complete diagnostic workup 16 (89%) 9 (64%) 8 (40%)
Abdominal ultrasound 8 (44%) 6 (43%) 8 (40%)
Fluid collection 3 0 0
Increased diameter of aneurysm 1 0 0
Helpfulness 4/8 (50%) 0 0
Screening abdominal CT 2 (11%) 1 (7%) -
Aneurysm 2 0 -
Suggestive of infected aneurysm or prosthesis 1 0 -
Helpfulness 2/2 (100%) 0 -
CT on account of PET/CT 3 (17%) 0 0
Aneurysm 2 - -
Suggestive of infected aneurysm or prosthesis 3 - -
Helpfulness 3/3 (100%) - -
FDG-PET/CT 13 (72%) 8 (57%) 9 (45%)
Focal uptake aneurysm 7 0 0
Focal uptake vascular prosthesis 3 0 0
Soft tissue inflammation 4 0 0
Para-aortal lymfadenopathy 1 0 0
Mediastinal lymfadenopathy 1 3 0
Unexpected findings 4 4 2
Helpfulness 10/13 (77%) 0 0
TTE 16 (89%) 13 (93%) 12 (60%)
Echocardiographic major criteria 0 0 0
Echocardiographic minor criteria 12 8 4
Helpfulness 1/16 (6%) 1/13† (8%) 0
TEE 6 (33%) 3 (21%) 4 (20%)
Echocardiographic major criteria 2 0 0
Echocardiographic minor criteria 6 1 3
Helpfulness 3/6 (50%) 1/3† (33%) 0
Antibiotic therapy 18 (100%) 7 (50%) 3 (15%)
Mortality during treatment 3 0 0
Ongoing treatment 13 7 2
Treatment completed successfully 2 0 1
Mean duration of treatment (months) 21.5 ± 6.4 [n = 2] - 2 [n = 1]
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observed, whereas echocardiographic minor criteria were
recorded in all of the performed TEEs. In 3 patients (50%),
TEE was considered helpful: 2 because of echocardio-
graphic major criteria and 1 as a result of aggravated pre-
existing valvular disease. In 4 out of 5 patients with no
definite localization and possible IE there were minor
echocardiographic criteria. In all 5 patients TTE was
performed. Two out of 5 TTE’s showed minor criteria. In
4 patients TEE was performed, 3 of which showed minor
criteria.
Long-term antibiotic treatment (doxycycline 200 mg/
day and hydroxychloroquine 600 mg/day) was given to
all patients. Thirteen patients (72%) are still under treat-
ment, 3 of whom are being treated for more than 18
months. Three patients (17%) died during the course of
therapy as a consequence of chronic Q fever infection.
Death from chronic Q fever was defined as death as a
result of active chronic infection. One patient died at 11
months following cardiac valve replacement due to pro-
gressive heart failure, probably as a result of artificial
valve dysfunction due to chronic Q fever. PCR on valve
tissue was positive. The second patient died in the
perioperative period (in the first month) due to bleeding
following acute aneurysm repair for a symptomatic
aneurysm. PCR on aneurysm tissue was positive for Q
fever. The third patient died in the perioperative period
(in the first month) due to SIRS following acute cardiac
valve replacement for severe Q fever endocarditis, with
tissue PCR being positive. In 2 patients (11%), treatment
was completed successfully after a treatment duration of
18 and 26 months with a follow-up after completion of
treatment of 16 and 4 months, respectively. Six patients
(33%) underwent surgery: abdominal aortic graft surgery
with open repair was performed in 1 patient, endovascular
aneurysm repair (EVAR) in 2 patients, first EVAR later
followed by abscess drainage, excision of infected tissue
Table 3 Diagnostics, treatment and outcomes in 52 patients with possible, probable and proven chronic Q fever*
(Continued)
Surgery 6 (33%) 0 0
Aortic graft surgery‡ 4 (22%) - -
Cardiac valve surgery 2 (11%) - -
Mortality 3 (17%) 0 0
*Adapted from Wegdam-Blans et al. [15].
†TTE and TEE were considered helpful in 2 patients where pre-existing valvulopathies aggravated.
‡One patient had surgery twice.
Bold texts summarize components of the table.
Abbrevations: PCR Polymerase chain reaction, CFT Complement fixation test, NA Not applicable, CT Computed tomography, 18F DG-PET/CT 18F- fluorodeoxyglucose
positron emission tomography combined with CT, TTE Transthoracic echocardiography, TEE Transesophageal echocardiography.
Figure 1 Titres of anti-phase 1 IgG at the time of chronic Q fever
diagnosis.
Figure 2 Titres of complement fixation test at the time of chronic
Q fever diagnosis. Abbrevations: CFT Complement fixation test.
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and lavage with omentum plasty in 1 patient, and cardiac
valve replacement in 2 patients.
Probable chronic Q fever
Probable chronic Q fever was diagnosed in 14 patients
(Table 1). In this group, 6 patients (43%) were immuno-
compromised (Table 2). Twelve patients (86%) experi-
enced symptomatic acute infection in the past. Two
patients (14%) experienced symptoms of chronic infec-
tion: fever and night sweats (n = 1), and weight loss and
fatigue (n = 1). The mean interval between acute Q fever
and analysis for chronic infection was 16 ± 11 months
(range: 1-41 months). While in 12 patients (86%) no
focus was localized, endocarditis (possible endocarditis
according to the modified Duke criteria) was regarded
as the most probable site of infection in 2 cases.
The median anti-phase I IgG titre at first analysis was
2048 (range: 1024-32768) and the median CFT-value was
320 (range: 80-5120). In 5 patients the anti-phase I IgG
titre decreased to < 1024. Of these 5 patients, 2 received
treatment for chronic Q fever and their anti-phase I IgG
titre decreased to < 1024 in 12 and 18 months, respect-
ively. In the 3 patients without treatment, anti-phase I IgG
titre decreased to < 1024 after 4, 10, and 12 months,
respectively.
A complete diagnostic work-up was performed in 9
patients (64%) (Table 3). Two patients were asymptom-
atic and considered low-risk, 1 patient refused further
analysis because of co-morbidity, and in 2 patients FDG-
PET/CT was postponed (because of recent surgery and
a concomitant severe pneumonia, respectively). FDG-
PET/CT was performed in 8 patients (57%). None of
these investigations localized infection (otherwise the
patient would have proven chronic Q fever). Four of the
performed FDG-PET/CT-scans (50%) revealed unex-
pected findings. These include mediastinal lymphaden-
opathy (eventually leading to the diagnosis of systemic
sclerosis) in 1 patient, and focal FDG-uptake in the
dental region in another patient. In 1 patient with mul-
tiple enlarged mediastinal lymph nodes, subsequent
broncheoalveolar lavage (BAL) did not lead to a definitive
diagnosis. In 1 patient, multiple unexpected findings were
observed (focal uptake in the left thyroid gland followed
by hemithyroidectomy leading to a diagnosis of adenoma
and multiple foci in the prostate and iliac bone, leading to
the diagnosis of prostate carcinoma). TTE was performed
in 13 patients (93%) and was considered helpful once
(8%), because progression of pre-existing valvular disease
was observed. In 8 patients (62%), echocardiographic
minor criteria were recorded. TEE was performed in 3
Figure 3 18F-FDG PET/CT image demonstrating a mycotic aneurysm. 18F-FDG PET/CT images (left column coronal sections, right column
transverse sections, upper row PET images, lower row PET/CT fusion images) of a patient with proven chronic Q fever demonstrating a mycotic
aneurysm and associated abscess adjacent to the left common iliac artery (arrows). Abbrevations: 18F DG-PET/CT 18F- fluorodeoxyglucose positron
emission tomography combined with CT.
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patients (21%), which was helpful in 1 patient. Echocardio-
graphic minor criteria were seen in 1 patient (33%).
Seven patients (50%) received long-term treatment with
antibiotics (doxycycline 200 mg/day and hydroxychloroquine
600 mg/day); none of these patients completed treatment
yet. Of the remaining 7 patients, a decision on treatment
was pending in 2 patients, 3 were not treated because of
severe co-morbidity, and 3 were asymptomatic and con-
sidered low-risk. All patients that were not on antibiotic
treatment were followed closely.
Possible chronic Q fever
Twenty patients were diagnosed with possible chronic Q
fever (Table 1). Thirteen (65%) patients could recall a
symptomatic episode of acute Q fever and none of the
patients experienced symptoms of chronic infection. The
mean interval between acute infection and analysis for
chronic Q fever was 7 ± 5 months (range: 1-15 months).
In 77% of the patients with possible chronic Q fever and
a previously known episode of acute Q fever, routine
serological follow-up at 3, 6, 9 and 12 months was
performed.
The median anti-phase I IgG titre at first analysis was
2048 (range: 1024-16384), and the median CFT-value
was 320 (range: 40-2560). In 8 patients, the anti-phase I
IgG titre decreased to < 1024, with an average of 7.5 ±
5.1 months. Of these patients, 1 patient was treated
and the anti-phase I IgG titre decreased to < 1024
within 7 months.
A complete diagnostic work-up was performed in 8
out of 20 patients (40%) (Table 3). Six patients were
asymptomatic and considered low-risk, 1 patient suffered
from severe co-morbidity, 3 patients were lost to follow-
up, and 2 patients were not yet completely analyzed. FDG-
PET/CT was performed in 9 patients (45%). None of these
investigations were helpful. Two FDG-PET/CT-scans
(22%) resulted in an unexpected finding: 1 patient with
FDG-uptake in the colon, followed by colonoscopy diag-
nosing a non-neoplastic polyp, and 1 patient with FDG-
uptake in the left clavicle, followed by CT that was normal.
TTE was performed in 12 patients (60%) and was consid-
ered helpful in none of the investigations. In 4 patients
(33%), echocardiographic minor criteria were recorded.
TEE was performed in 4 patients (20%), being helpful in
none of the patients. Echocardiographic minor criteria
were seen in 3 patients (75%).
Long-term antibiotic treatment was prescribed to
three patients (15%) because of debilitating symptoms
(severe fatigue and muscle ache). One of these patients
initially started treatment because of suspected chronic
Q fever, but stopped after 2 months because anti-phase I
IgG titres were rapidly decreasing. The 2 other patients
had not completed treatment yet. Of the remaining 17
patients, 11 were considered low-risk, in 5 a decision on
treatment was pending, and 1 patient had severe co-
morbidity.
Comparison between patients with proven chronic Q
fever and patients with probable and possible chronic Q
fever
In order to evaluate potential differences between patients
with proven chronic Q fever and those with possible or
probable chronic Q fever, data were compared by univari-
ate analysis (Table 4). Age at diagnosis, history of smoking,
and mean interval from acute infection to analysis for
chronic Q fever did not differ significantly between the
groups. Male sex (p = 0.04) and symptomatic chronic
infection (p < 0.01) were significantly more present in
patients with proven chronic Q fever. Concerning risk
factors, which were found previously in other studies,
the presence of pre-existing valvular disease, indication
for endocarditis prophylaxis, and immunodeficiency did
not differ significantly between the groups in our study.
In contrast, cardiac valve prostheses (p = 0.01), known
aneurysms (p < 0.01), and vascular prostheses (p < 0.01)
were significantly associated with proven chronic Q fever.
Anti-phase I IgG (p = 0.01) and CFT-values (p < 0.01)
were significantly higher in patients with proven chronic
Q fever when compared to the groups of probable and
possible Q fever combined (Figures 1 and 2). Also, the
mean time to anti-phase I IgG < 1024 was significantly
longer in this group (p < 0.01). In contrast to AUS and
FDG-PET/CT, the helpfulness of CT, TTE and TEE
showed no significant differences between the groups. Both
antibiotic treatment (p < 0.01) and surgery (p < 0.01) were
used more often in patients with proven chronic Q fever.
Most importantly, a clear association was seen between
proven chronic Q fever and mortality rates (p = 0.03).
Analysis after adjustments to the modified Duke criteria
The modified Duke criteria and the 2 aforementioned
adjustments to these criteria were applied to all patients
(Table 5). Applying the modified Duke criteria, 4 cases
of definite IE were diagnosed, and 20 cases of possible
IE. Of 20 patients with possible IE (all groups), 11 out of
19 patients who underwent TTE had minor criteria by
TTE, and 4 out of 7 patients who underwent TEE had
minor criteria. When echocardiographic minor criteria
were included (first adjustment), 8 cases were considered
definite IE and 28 cases possible IE. Including a positive
serum PCR for C. burnetii as a major criterion (second
adjustment), 12 patients scored definite IE and 14 pos-
sible IE. The modified Duke criteria were compared with
the modified Duke criteria including our first and sec-
ond adjustments, respectively, by a 2-tailed Wilcoxon-
test, which showed significant differences (p = 0.046 and
p < 0.01, respectively).
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Table 4 Significant differences between patients with proven chronic Q fever and patients with probable and possible
chronic Q fever (univariate analysis)*
Proven chronic Q fever: Probable and possible chronic Q fever: Significance (p)
Number of patients Number of patients
(% or range) (% or range)
Patient characteristics
Number of patients 18 34
Male sex 17 (94%) 19 (56%) 0.04
Symptomatic chronic infection 14 (78%) 2 (6%) <0.0001
Cardiac valve prosthesis 4 (22%) 0 0.01
Known aneurysm 8 (44%) 1 (3%) 0.0004
Abdominal aortic aneurysm, infrarenal 7 (39%) 0 0.0003
Vascular prosthesis 11 (61%) 4 (12%) 0.004
Co-morbidities 18 (100%) 22 (65%) 0.021
Diagnostic work-up 16 (89%) 17 (50%) 0.04
Positive serum PCR 12 (67%) 0 <0.0001
Positive tissue PCR 6 (33%) 0 0.011
Anti-phase I IgG at diagnosis 4096 (256-65536) 2048 (1024-32768) 0.013
CFT at diagnosis 1280 (0-20480) 320 (40-5120) 0.001
Time to anti-phase I IgG <1024 (months) 23.3 ± 7.9 [n = 4] 9.5 ± 5.2 [n = 13] 0.001
Helpfulness of abdominal ultrasound 4/8 (50%) 0/14 (0%) 0.01
Helpfulness of FDG-PET/CT 10/13 (77%) 0 <0.0001
Antibiotic therapy 18 (100%) 10 (29%) <0.0001
Mortality during treatment 3/18 (17%) 0 0.037
Ongoing treatment 13/18 (72%) 9/10 (90%) 0.008
Surgery 6 (33%) 0 0.001
Aortic graft surgery† 4 (22%) 0 0.011
Cardiac valve surgery 2 (11%) 0 NS
Mortality 3 (17%) 0 0.033
*Adapted from Wegdam-Blans et al. [15].
†One patient had surgery twice.
Bold texts summarize components of the table.
Abbrevations: PCR polymerase chain reaction, CFT complement fixation test, FDG-PET/CT 18F- fluorodeoxyglucose positron emission tomography, NS not significant.
Table 5 Comparison of (adjustments to) modified Duke criteria: complete case series
Modified Duke
criteria [27]
Modified Duke criteria,
including echocardiographic
minor criteria [31]
Significance† (comparison
with modified Duke
criteria) (p)‡
Modified Duke criteria,
including PCR as a
major criterion [30]
Significance† (comparison
with modified Duke
criteria) (p)§
Definite IE 4 (9%) 8 (19%) 0.046 12 (28%) 0.005
Possible IE 20 (47%) 28 (65%) 0.046 14 (33%) 0.034
Rejected IE 19 (44%) 7 (16%) 0.001 17 (40%) 0.157
Total 43* 43* - 43* -
†Wilcoxon test, 2-tailed.
‡Modified Duke criteria compared to ‘modified Duke criteria, including echocardiographic minor criteria’.
§Modified Duke criteria compared to ‘modified Duke criteria, including PCR as a major criterion’.
*Nine patients were not examined by echocardiography; the modified Duke criteria could therefore not be calculated.
Abbrevations: PCR polymerase chain reaction, IE infective endocarditis.
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Discussion
In this study, the diagnostic work-up of 52 patients with
chronic Q fever according to the Dutch consensus on Q
fever diagnostics was evaluated. We demonstrated that
FDG-PET/CT might be a valuable tool for localization
of vascular infection with C. burnetii. It was shown that
infected aneurysms or vascular prostheses are the most
common manifestation of proven chronic Q fever in our
population.
The mean age of patients was similar to previously
reported case series of chronic Q fever [6,8,17]. The
overall male predominance has been shown before as
well, but the portion of male patients with proven
chronic Q fever (94%) was distinct. This possibly results
from a higher incidence of aneurysms and cardiovascular
disease in male subjects, which are clear risk factors for
developing chronic Q fever [3,8,33]. A history of smok-
ing was established as a risk factor for chronic Q fever,
especially in those patients with proven chronic Q fever.
Smoking was not included in the possible risk factors for
developing chronic Q fever in the recently published
Dutch study by Kampschreur et al. [33]. Furthermore,
patients with proven chronic Q fever more often had a
cardiac valve prosthesis, a known aneurysm, or a vascular
prosthesis as was also found by Kampschreur et al. [33].
Although reported in some previous studies, pre-existing
valvular disease other than valve prosthesis did not appear
to be an important risk factor in this study [6,14,33]. A
similar observation was done by another Dutch group
[34,35], that found a low risk of progression to Q fever
endocarditis in the presence of degenerative valvular
disease.
Only 44% of patients with proven chronic Q fever
could recall an episode of acute Q fever, compared to
74% of those with possible/probable Q fever. Symptom-
atic acute infection most often results in antibiotic treat-
ment, which might reduce the chance of developing
proven chronic Q fever. In addition, in patients with
acute Q fever, serological follow-up is performed while
this was of course not the case in patients without symp-
tomatic (and thus usually unknown) infection. It is pos-
sible that elevating titres of IgG anti-phase I titres found
during follow-up led to earlier diagnosis and treatment,
possibly preventing progression from possible and probable
chronic Q fever to proven chronic Q fever.
A large retrospective study from France identified
endocarditis as the predominant manifestation of chronic
Q fever (73% of cases) [8]. In contrast, only 22% of our pa-
tients with proven chronic Q fever have been diagnosed
with Q fever endocarditis. Infected aneurysms and
infected vascular prostheses were found in 39% and
17% of patients, respectively. It has been suggested that
mycotic aneurysms may be caused by non-diagnosed
endocarditis in patients with chronic Q fever. However,
applying the modified Duke criteria to all patients with
proven chronic Q fever, only 1 patient had an infected
vascular prosthesis and definite IE at the same time.
One patient with an infected vascular prosthesis and 1
patient with an infected aneurysm had rejected IE
according to the modified Duke criteria. The last pa-
tient with an infected vascular prosthesis and all other
patients with an infected aneurysm had possible IE
according to the modified Duke criteria. The cause of
this striking difference in predominant manifestation
of chronic Q fever remains largely unclear, and prob-
ably results from a combination of factors. First, most
patients in other series were evaluated because of
endocarditis, whereas in our case series, also other
complaints (fever, night sweats, presence of aneurysm)
and routine serological follow up after acute Q fever
led to evaluation for Q fever because of the current
epidemic. In addition, not all patients underwent echo-
cardiography, possibly leading to an underestimation
of endocarditis in our group. Furthermore, it is pos-
sible that in those patients without a full diagnostic
work-up only one site of infection was notified,
whereas it is possible that patients had 2 sites of infec-
tion. Second, pre-existing valvular disease was seen
less often in this case series than in those patients
reported in literature. This could be influenced by the
fact that screening echocardiography is not performed
in patients with acute Q fever in the Netherlands. Al-
though our study did not found pre-existing valvular
disease to be a significant risk factor for proven
chronic Q fever, this contrasts with previous studies
[6,14], but is in accordance with the other Dutch study
on risk factors for developing proven chronic Q fever
[33]. Third, the Dutch C. burnetii strain is possibly
more likely to cause endovascular infection other than
endocarditis. Even though it is possible that more vas-
cular infections were found because FDG-PET/CT was
performed more often, it is unlikely that vascular infec-
tions would go unnoticed in other chronic Q fever
series, in which hardly any vascular infection was seen.
If these patients would have had unidentified vascular
infection in addition to endocarditis, more complica-
tions would be expected because of the high mortality
rate of vascular chronic Q fever, even in case of opti-
mal (surgical) treatment. Finally, it is not clear if other
research groups applied the modified Duke criteria in
the same strict manner as we did for this study.
In 1994, Durack et al. [31] introduced a new set of
diagnostic criteria for IE that subsequently came to be
known as the Duke criteria. Li and colleagues [27] pro-
posed modifications to the Duke criteria in 2000, adding
a positive serology for C. burnetii as a major criterion,
which had already been proposed earlier by Fournier
et al. [18]. In addition, the modifications included the
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elimination of echocardiographic minor criteria, because
a widespread use of TEE was assumed. It is well-
recognized that the sensitivity of these criteria is dimin-
ished in Q fever endocarditis, since it is known for its
subtle valve abnormalities and absence of vegetations
[4,18,24]. Nonetheless, we strictly applied the modified
Duke criteria to this case series, resulting in only 4
patients (9%) with definite IE and 20 patients (47%) with
possible IE. Even if we merely reflect on patients with
proven chronic Q fever, the percentage of definite IE was
only 22%. There were another 5 patients (28%) with an
unidentified focus, 4 of whom had possible IE according
to the modified Duke criteria. TEE was performed in a mi-
nority of patients (25%), while the elimination of echocar-
diographic minor criteria was based on the widespread
use of TEE [27]. We cannot rule out the possibility that in
some patients vegetations were missed because TTE was
conducted exclusively.
In the past, several adjustments have been proposed to
further improve the sensitivity of the modified Duke cri-
teria. One of these adjustments was the use of PCR tech-
niques as a major criterion [30], which is not implemented
in international guidelines. However, in a recent study on
Q fever endocarditis [6], a positive serum PCR served as
major criterion. It is not clear whether PCR was an add-
itional major criterion or served as substitute for serology.
The theoretical addition of a positive serum PCR as major
criterion to the modified Duke criteria appeared most use-
ful. From our experience, we suggest that a positive serum
PCR for C. burnetii in patients with chronic Q fever with-
out an identified site of infection should be treated as Q
fever endocarditis. Furthermore, the presence of echocar-
diographic minor criteria should raise the clinician’s suspi-
cion of endocarditis, and TEE should be performed in all
patients with chronic Q fever with an unknown focus. It is
essential to bear in mind that the Duke criteria are useful
for the classification of IE, but that they were designed for
research purposes and thus should not replace clinical
judgment in clinical practice.
CT was performed initially in only 2 patients with
proven chronic Q fever, making it impossible to estimate
the helpfulness of this technique. In contrast, FDG-PET/
CT, localized infection in 77% of patients with proven
chronic Q fever, which suggests that FDG-PET/CT is a
valuable tool for the localization of vascular Q fever in-
fection. FDG-PET/CT is also very well suited for diag-
nosing osteomyelitis, which is another possible focus of
chronic Q fever. A well-recognized disadvantage of FDG-
PET/CT is its specificity, as it does not differentiate be-
tween inflammation, infection, and malignancy. As such,
unexpected findings were observed in 9 patients (30%), in-
cluding the detection of previously unknown malignancies
in 2 patients and newly diagnosed systemic sclerosis in
another 2 patients. Five patients underwent invasive
diagnostic procedures as a result of suspected malignan-
cies, but pathological examination remained negative.
The number of unexpected findings is higher than
found in previous studies on the use of FDG-PET in
other infections and fever of unknown origin (FUO)
[36,37], which might be explained by the higher age of
the patients and the male predominance in combination
with a higher than average percentage of smokers, in-
creasing the risk of associated malignancy when com-
pared to patients with FUO. A limitation of our study is
of course its retrospective character. Unfortunately, not
all patients underwent a complete diagnostic work-up.
Therefore, it is important to bear in mind that some pa-
tients might have had two sites of infection, which
might have been missed. This emphasizes the need for a
full diagnostic work-up in patients with chronic Q fever.
Also, the time point of diagnostic imaging in the course
of infection differed between the patients, which might
have influenced the helpfulness.
Conclusions
In conclusion, if chronic Q fever is diagnosed, FDG-
PET/CT is a helpful imaging technique for localization
of vascular infection. Patients with proven chronic Q
fever were diagnosed significantly more often with my-
cotic aneurysms than in previous case series. Theoret-
ical adjustment of the modified Duke criteria by adding
serum PCR as a major criterion results in more diagno-
ses of Q fever endocarditis. We recommend treating pa-
tients with chronic Q fever with a positive serum PCR
for C. burnetii without an identified site of infection as
Q fever endocarditis. To increase sensitivity after previ-
ous exclusion of echocardiographic minor criteria from
the modified Duke criteria, TEE is recommended in pa-
tients with chronic Q fever. A minority of all patients
with proven chronic Q fever recalls a previous episode
of acute Q fever, so clinical suspicion should remain
high, especially in endemic regions.
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